Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

Peter J. Houghton, Raushan T. Kurmasheva, E. Anders Kolb, Jianrong Wu, Richard Gorlick, John M. Maris, Malcolm A. Smith

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

TAK-701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c-Met transduced signaling and c-Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK-701 based on immunochemical detection of HGF/c-Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK-701 was tested using a dose of 30mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK-701 did not induce significant differences in EFS distribution in treated tumors compared to control tumors. Objective responses were not observed in any of the tested solid tumor xenografts.

Original languageEnglish (US)
Pages (from-to)380-382
Number of pages3
JournalPediatric Blood and Cancer
Volume61
Issue number2
DOIs
StatePublished - Feb 2014
Externally publishedYes

Keywords

  • C-Met inhibition
  • Developmental therapeutics
  • Preclinical testing

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program'. Together they form a unique fingerprint.

Cite this